<DOC>
	<DOCNO>NCT02651610</DOCNO>
	<brief_summary>The primary purpose research study see whether add bavituximab ( investigational drug ) standard chemotherapy drug taxane , improve result treatment HER2-negative metastatic breast cancer .</brief_summary>
	<brief_title>Taxane Therapy With Without Bavituximab Treatment HER2-Negative Metastatic Breast Cancer</brief_title>
	<detailed_description>This open-label randomized trial patient HER2-negative metastatic breast cancer . Patients treat either taxane alone ( investigator choice paclitaxel docetaxel ) taxane bavituximab . Paclitaxel give 3 4 week , docetaxel give every 3 week , bavituximab give weekly . All therapy continue disease progression , toxicity , withdrawal consent , investigator decision , study termination . Efficacy ( overall response rate ) primary endpoint safety secondary endpoint .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Taxane</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Inclusion Criteria 1 . Written inform consent obtain prior screen . 2 . Females male least 18 year age . 3 . Histologically cytologically document metastatic HER2negative breast cancer . 4 . Measurable disease per RECIST 1.1 ( Phase II ) ; evaluable disease ( Phase III ) 5 . ECOG performance status 0 1 . 6 . Adequate hematologic function : absolute neutrophil count ≥1500 cells/µL ; hemoglobin ≥9 g/dL ; platelet ≥100,000/µL . 7 . Adequate renal function : serum creatinine ≤1.8 mg/dL calculate creatinine clearance &gt; 50 mL/min use CockcroftGault equation . 8 . Adequate hepatic function : total bilirubin ≤ upper limit normal ( ULN ) , serum albumin ≥3.0 g/dL , alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) ≤1.5 × ULN . ALT and/or AST may ≤5 × ULN due liver metastasis . If ALT AST &gt; 1.5 ≤5 × ULN patient liver metastasis , alkaline phosphatase must ≤2.5 × ULN . Patients Gilbert 's syndrome allow total bilirubin ≤2 × ULN direct bilirubin ≤ULN . 9 . Prothrombin time ( PT ) and/or international normalize ratio ( INR ) ≤1.5 × ULN activate partial thromboplastin time ( aPTT ) ≤1.5 × ULN patient anticoagulant therapy ( therapeutic PT and/or INR aPTT acceptable patient anticoagulant ) . 10 . Patients must negative serum human chorionic gonadotropin test within 1 week Day 1 ( pregnancy test require patient bilateral oophorectomy and/or hysterectomy patient &gt; 1 year postmenopausal ) . 11 . All patient reproductive potential ( ie , surgically sterile postmenopausal ) must agree use highly effective method contraception ( &lt; 1 % failure rate per year ) 3 month end study treatment ( female ) 6 month end study treatment ( male ) . Exclusion Criteria 1 . HER2positive breast cancer . 2 . Less 6 month since last dose prior adjuvant nontaxane regimen . 3 . Less 12 month since last dose prior adjuvant taxanecontaining regimen . 4 . Any chemotherapy regimen MBC within 3 week Day 1 . 5 . Known history bleed diathesis coagulopathy ( eg , von Willebrand disease hemophilia ) . 6 . Bleeding : Clinically significant bleeding , gross hematuria , gastrointestinal bleeding , hemoptysis within 6 month screen , unless cause identify adequately treat ( eg , cystitis , ulcer ) . Minor biopsyrelated bleed last &lt; 24 hour resolve least 1 week Day 1 allow . 7 . Thromboembolic event ( eg , deep vein thrombosis , pulmonary embolism , arterial thrombosis ) within 6 month screen . 8 . Grade 2 high peripheral neuropathy ( eg , numbness , tingle , and/or pain distal extremity ) . 9 . Radiotherapy within 1 week precede Day 1 ; ongoing acute toxicity prior radiotherapy . 10 . Either symptomatic clinically active brain metastasis ( ie , require ongoing treatment ) . Patients eligible brain metastasis adequately treat . Patients must either corticosteroids , stable decrease dose ≤10 mg daily prednisone ( equivalent ) . 11 . Major surgery within 4 week Day 1 . 12 . Uncontrolled intercurrent disease ( eg , diabetes , hypertension , thyroid disease , active infection ) . 13 . Autoimmune disease , treat immunosuppressive drug ( eg , methotrexate biological agent ) , condition require immunosuppressive therapy ( eg , prior allotransplantation ) . 14 . History hypersensitivity bavituximab , docetaxel , paclitaxel , excipients . 15 . Symptomatic coronary artery disease , cerebrovascular accident transient ischemic attack , myocardial infarction , arterial embolism , unstable angina pectoris within 6 month screen . 16 . Currently pregnant , nursing , plan pregnancy study . 17 . Investigational therapy within 28 day prior Day 1 . 18 . Patient condition situation , investigator 's opinion , may put patient significant risk , may confound study result , may interfere significantly patient 's participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>PPHM 1401</keyword>
	<keyword>bavituximab</keyword>
	<keyword>Peregrine</keyword>
	<keyword>Breast Cancer</keyword>
	<keyword>HER-2 Negative</keyword>
	<keyword>HER2 Negative</keyword>
</DOC>